Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Matthieu Beuvelet"'
Autor:
Alexia Kieffer, Matthieu Beuvelet, Gerald Moncayo, Mersha Chetty, Aditya Sardesai, Robert Musci, Richard Hudson
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 10, Pp 2135-2153 (2024)
Abstract Introduction Respiratory syncytial virus (RSV) leads to significant morbidity in newborn infants in the United Kingdom (UK). Nirsevimab, a long-acting monoclonal antibody, received approval from the European Medicines Agency and has been lic
Externí odkaz:
https://doaj.org/article/5564bff80f2a41beaf6fcbd72e81efd2
Autor:
Ruth Gil-Prieto, Jaime Jesus Pérez, Georgina Drago, Alexia Kieffer, Julie Roïz, Paulina Kazmierska, Aditya Sardesai, Solène de Boisvilliers, Juan Luis López-Belmonte, Matthieu Beuvelet, Javier Alvarez Aldean
Publikováno v:
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Background Respiratory syncytial virus (RSV) is associated with substantial morbidity among infants. This study modelled the potential public health and economic impact of nirsevimab, a long-acting monoclonal antibody, as an immunoprophylact
Externí odkaz:
https://doaj.org/article/666c4cefd3bd45338d8cbfd55b48a6b8
Autor:
Alexia Kieffer, Matthieu Beuvelet, Aditya Sardesai, Robert Musci, Sandra Milev, Jason K H Lee
Publikováno v:
The Journal of infectious diseases.
Autor:
Alexia Kieffer, Matthieu Beuvelet, Aditya Sardesai, Robert Musci, Sandra Milev, Julie Roiz, Jason K H Lee
Publikováno v:
The Journal of infectious diseases. 226(Suppl 2)
Background Respiratory syncytial virus (RSV) is associated with substantial morbidity in the United States, especially among infants. Nirsevimab, an investigational long-acting monoclonal antibody, was evaluated as an immunoprophylactic strategy for